Ruxolitinib vs placebo
Health‐related quality of life Patients that achieved a reduction of 50% or more in the total MF Symptom Assessment Form · Patients with treating MF
Ruxolitinib may leads to higher health‐related quality of life Patients that achieved a reduction of… compared with placebo (low certainty).
1 finding from 1 review
- Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis 2015 · Cochrane Headline outcomes onlyRR 8.82 [4.4, 17.69]1 study · 309 participantsLow